Brinker Capital Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Brinker Capital Investments’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Sell	3,491 -46	-1%	-$23.6K	0.01%	829
2026 Q1	$1.85M	Sell	3,537 -1,813	-34%	-$866K	0.02%	790
2025 Q4	$3.12M	Buy	5,350 +1,259	+31%	+$643K	0.02%	633
2025 Q3	$1.88M	Buy	4,091 +453	+12%	+$169K	0.01%	868
2025 Q2	$1.1M	Buy	3,638 +47	+1%	+$14K	0.01%	1147
2025 Q1	$1.19M	Buy	3,591 +497	+16%	+$163K	0.01%	990
2024 Q4	$955K	Sell	3,094 -90	-3%	-$25.3K	0.01%	1080
2024 Q3	$676K	Sell	3,184 -293	-8%	-$75K	0.01%	1216
2024 Q2	$974K	Buy	+3,477	New	+$828K	0.01%	1007

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brinker Capital Investments's MDGL Position: Q2 2026 in Review

Brinker Capital Investments reduced its Madrigal Pharmaceuticals (MDGL) stake by 1.3% in Q2 2026, selling an estimated $23.6K and leaving 3,491 shares worth $1.87M. The position accounts for 0.01% of the portfolio, ranked #829.

Brinker Capital Investments first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.12M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Brinker Capital Investments held 3,491 shares of Madrigal Pharmaceuticals worth $1.87M as of Q2 2026.
Brinker Capital Investments sold 46 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $23.6K.
Madrigal Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #829 holding.
Brinker Capital Investments first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Brinker Capital Investments's Madrigal Pharmaceuticals position peaked at $3.12M in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.